Early symptom improvements predict later clinical response and remission at week 12 for patients with ulcerative colitis treated with mirikizumab in the LUCENT-1 study

被引：0

作者：

Schreiber, S. W. ^{[1
]}

Issacs, K. ^{[2
]}

Zhu, B. ^{[3
]}

Wu, J. ^{[3
]}

Keohane, A. ^{[3
]}

Redondo, I ^{[3
]}

Owen, C. ^{[3
]}

Navabi, S. ^{[4
]}

机构：

[1] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany

[2] Univ North Carolina, Med, Chapel Hill, NC USA

[3] Eli Lilly & Co, Lilly Immunol, Indianapolis, IN USA

[4] United Med Doctors, Gastroenterol, Fountain Valley, CA USA

来源：

关键词：

D O I：

10.1093/ecco-jcc/jjae190.0840

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P0666

引用

页码：i1304 / i1306

页数：3